Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936117 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00936117: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00936117 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936117, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn the amount of posaconazole that is in the body at different time points when given to patients with leukemia. The safety of this drug will also be studied. Objectives: Primary: To study the plasma pharmacokinetics of posaconazole in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) undergoing induction chemotherapy or relapsed or refractory patients who will receive salvage chemotherapy. Secondary: To evaluate the safety of posaconazole given as prophylaxis.
Interventions
- DRUG Posaconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936117
The ClinicalTrials.gov registry entry for NCT00936117 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Posaconazole is the first listed.
NCT00936117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936117 about?
NCT00936117 is a clinical study titled "Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia". The goal of this clinical research study is to learn the amount of posaconazole that is in the body at different time points when given to patients with leukemia. The safety of this drug will also be studied. Objectives: Primary: To study the plasma pharmacokinetics of posaconazole in patients wi...
What is the current status of trial NCT00936117?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2009-09. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00936117?
The interventions under investigation include: Posaconazole (DRUG).
Who is sponsoring clinical trial NCT00936117?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.